A I Daud

Summary

Affiliation: University of California
Country: USA

Publications

  1. ncbi Management of pegylated interferon alpha toxicity in adjuvant therapy of melanoma
    Adil Daud
    University of California, San Francisco, Melanoma Program, San Francisco 1600 Divisadero St, Rm A741, Box 1770, San Francisco, CA 94115, USA
    Expert Opin Biol Ther 12:1087-99. 2012
  2. ncbi Phase I study of bosutinib, a src/abl tyrosine kinase inhibitor, administered to patients with advanced solid tumors
    Adil I Daud
    H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA
    Clin Cancer Res 18:1092-100. 2012
  3. ncbi Potentiation of a topoisomerase I inhibitor, karenitecin, by the histone deacetylase inhibitor valproic acid in melanoma: translational and phase I/II clinical trial
    Adil I Daud
    Experimental Therapeutics Program, H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA
    Clin Cancer Res 15:2479-87. 2009
  4. ncbi Phenotypic and functional analysis of dendritic cells and clinical outcome in patients with high-risk melanoma treated with adjuvant granulocyte macrophage colony-stimulating factor
    Adil I Daud
    H Lee Moffitt Cancer Center, Tampa, FL, USA
    J Clin Oncol 26:3235-41. 2008
  5. ncbi Pharmacokinetic/pharmacodynamic analysis of adjuvant pegylated interferon α-2b in patients with resected high-risk melanoma
    A I Daud
    Division of Hematology Oncology, University of California, San Francisco, San Francisco, CA, USA
    Cancer Chemother Pharmacol 67:657-66. 2011
  6. ncbi Phase I trial of interleukin-12 plasmid electroporation in patients with metastatic melanoma
    Adil I Daud
    Cutaneous Oncology and Experimental Therapeutics Programs, H Lee Moffitt Cancer Center, University of South Florida, Tampa, FL, USA
    J Clin Oncol 26:5896-903. 2008
  7. ncbi Phase I clinical trial of the Src inhibitor dasatinib with dacarbazine in metastatic melanoma
    A P Algazi
    University of California, San Francisco, MTZ A741, 1600 Divisadero Street, San Francisco, CA 94143, USA
    Br J Cancer 106:85-91. 2012
  8. ncbi Phase II trial of sagopilone, a novel epothilone analog in metastatic melanoma
    R C DeConti
    Moffitt Cancer Center, 12902 Magnolia Drive, Tampa, FL, USA
    Br J Cancer 103:1548-53. 2010
  9. ncbi In vivo synergy between topoisomerase II and histone deacetylase inhibitors: predictive correlates
    Douglas C Marchion
    Department of Interdisciplinary Oncology, Experimental Therapeutics Program, H Lee Moffitt Cancer Center and Research Institute, 12902 Magnolia Drive SRB 22007, Tampa, FL 33612, USA
    Mol Cancer Ther 4:1993-2000. 2005
  10. ncbi Valproic acid alters chromatin structure by regulation of chromatin modulation proteins
    Douglas C Marchion
    Department of Interdisciplinary Oncology, Experimental Therapeutics Program, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida 33612, USA
    Cancer Res 65:3815-22. 2005

Detail Information

Publications20

  1. ncbi Management of pegylated interferon alpha toxicity in adjuvant therapy of melanoma
    Adil Daud
    University of California, San Francisco, Melanoma Program, San Francisco 1600 Divisadero St, Rm A741, Box 1770, San Francisco, CA 94115, USA
    Expert Opin Biol Ther 12:1087-99. 2012
    ..PegIFNα2b is therefore a valuable alternative option for adjuvant treatment in melanoma, with a toxicity profile similar to that of HDI overall but a more convenient administration schedule...
  2. ncbi Phase I study of bosutinib, a src/abl tyrosine kinase inhibitor, administered to patients with advanced solid tumors
    Adil I Daud
    H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA
    Clin Cancer Res 18:1092-100. 2012
    ..Primary efficacy endpoints for part 2 were median progression-free survival (colorectal and non-small cell lung) and median overall survival (pancreas)...
  3. ncbi Potentiation of a topoisomerase I inhibitor, karenitecin, by the histone deacetylase inhibitor valproic acid in melanoma: translational and phase I/II clinical trial
    Adil I Daud
    Experimental Therapeutics Program, H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA
    Clin Cancer Res 15:2479-87. 2009
    ..We examined whether histone deacetylase inhibition could potentiate the DNA strand cleavage, cytotoxicity as well as the clinical toxicity, and efficacy of KTN in melanoma...
  4. ncbi Phenotypic and functional analysis of dendritic cells and clinical outcome in patients with high-risk melanoma treated with adjuvant granulocyte macrophage colony-stimulating factor
    Adil I Daud
    H Lee Moffitt Cancer Center, Tampa, FL, USA
    J Clin Oncol 26:3235-41. 2008
    ..We hypothesized that GM-CSF-stimulated DC differentiation may result in clinical benefit in patients with high-risk melanoma...
  5. ncbi Pharmacokinetic/pharmacodynamic analysis of adjuvant pegylated interferon α-2b in patients with resected high-risk melanoma
    A I Daud
    Division of Hematology Oncology, University of California, San Francisco, San Francisco, CA, USA
    Cancer Chemother Pharmacol 67:657-66. 2011
    ..We investigated the pharmacokinetics (PK) and safety of high-dose peginterferon α-2b in patients with high-risk melanoma...
  6. ncbi Phase I trial of interleukin-12 plasmid electroporation in patients with metastatic melanoma
    Adil I Daud
    Cutaneous Oncology and Experimental Therapeutics Programs, H Lee Moffitt Cancer Center, University of South Florida, Tampa, FL, USA
    J Clin Oncol 26:5896-903. 2008
    ..In vivo electroporation, in preclinical models, significantly enhances gene transfer efficiency while retaining the safety advantages of plasmid DNA...
  7. ncbi Phase I clinical trial of the Src inhibitor dasatinib with dacarbazine in metastatic melanoma
    A P Algazi
    University of California, San Francisco, MTZ A741, 1600 Divisadero Street, San Francisco, CA 94143, USA
    Br J Cancer 106:85-91. 2012
    ..Src inhibitors sensitise melanoma cells to chemotherapy in preclinical models. The combination of dasatinib and dacarbazine was tested in a phase I trial in melanoma...
  8. ncbi Phase II trial of sagopilone, a novel epothilone analog in metastatic melanoma
    R C DeConti
    Moffitt Cancer Center, 12902 Magnolia Drive, Tampa, FL, USA
    Br J Cancer 103:1548-53. 2010
    ..Sagopilone is a novel fully synthetic epothilone with promising preclinical activity and a favourable toxicity profile in phase I testing...
  9. ncbi In vivo synergy between topoisomerase II and histone deacetylase inhibitors: predictive correlates
    Douglas C Marchion
    Department of Interdisciplinary Oncology, Experimental Therapeutics Program, H Lee Moffitt Cancer Center and Research Institute, 12902 Magnolia Drive SRB 22007, Tampa, FL 33612, USA
    Mol Cancer Ther 4:1993-2000. 2005
    ..Ex vivo comet assays may be useful as a predictive tool when tumor cells are limited and serial biopsies are difficult to obtain...
  10. ncbi Valproic acid alters chromatin structure by regulation of chromatin modulation proteins
    Douglas C Marchion
    Department of Interdisciplinary Oncology, Experimental Therapeutics Program, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida 33612, USA
    Cancer Res 65:3815-22. 2005
    ..The proposed mechanism of action suggests an effect of drug sequencing on the antitumor activity of these drugs...
  11. ncbi Overall and progression-free survival in metastatic melanoma: analysis of a single-institution database
    M Aleem Khan
    Department of Cutaneous Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA
    Cancer Control 13:211-7. 2006
    ..CONCLUSIONS: In this retrospective review of patients treated at a single institution, those treated with multiagent chemotherapy but not with single-agent DTIC appeared to have had a survival benefit...
  12. ncbi Src activation in melanoma and Src inhibitors as therapeutic agents in melanoma
    Jade Homsi
    Cutaneous Oncology, H Lee Moffitt Cancer Center, Tampa, Florida 33612, USA
    Melanoma Res 19:167-75. 2009
    ..Src inhibitors may be a promising therapy in melanoma, either by themselves or in combination with chemotherapy (especially with platinum compounds) or inhibitors of the Akt/PI3k pathway...
  13. ncbi Sequence-specific potentiation of topoisomerase II inhibitors by the histone deacetylase inhibitor suberoylanilide hydroxamic acid
    Douglas C Marchion
    Department of Interdisciplinary Oncology, Experimental Therapeutics Program, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida 33612, USA
    J Cell Biochem 92:223-37. 2004
    ..These findings may impact the clinical development of combining HDAC inhibitors with DNA damaging agents...
  14. ncbi Synergistic interaction between histone deacetylase and topoisomerase II inhibitors is mediated through topoisomerase IIbeta
    Douglas C Marchion
    Experimental Therapeutics Program, Department of Interdisciplinary Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida 33612, USA
    Clin Cancer Res 11:8467-75. 2005
    ..CONCLUSIONS: The recruitment of topoisomerase IIbeta as a target may overcome primary or emergent drug resistance to topoisomerase II-targeting agents and hence may broaden the applicability of this important class of anticancer agents...
  15. ncbi Immunotherapy as part of a multidisciplinary approach to melanoma treatment
    Adam I Riker
    Cutaneous Oncology, H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida 33612, USA
    Front Biosci 11:1-14. 2006
    ..This in turn will provide us with new insight and direction as we design the next generation of vaccines for patients with advanced cancer and in particular melanoma...
  16. ncbi Activated stat-3 in melanoma
    Jane L Messina
    Pathology Service, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA
    Cancer Control 15:196-201. 2008
    ..We examined the expression of phosphorylated Stat-3 (pStat-3), activated Stat-1 (pStat-1) and interferon alpha receptor subunit 1(IFNAR-1) in human melanocytic neoplasms...
  17. ncbi Phase I trial of poly-L-glutamate camptothecin (CT-2106) administered weekly in patients with advanced solid malignancies
    Jade Homsi
    H Lee Moffitt Cancer Center, Tampa, Florida 33612 9497, USA
    Clin Cancer Res 13:5855-61. 2007
    ..We studied a weekly schedule of CT-2106 in patients with refractory solid tumor malignancies...
  18. ncbi Uncommon manifestations of common malignancies: case 3. Malignant melanoma arising from a spinal nerve root
    Aung Naing
    H. Lee Moffitt Cancer Center and Research Institute, Cutaneous Oncology and Neurosurgery Program, Tampa, FL, USA
    J Clin Oncol 22:3194-5. 2004
  19. ncbi State of the science 60th anniversary review: 60 Years of advances in cutaneous melanoma epidemiology, diagnosis, and treatment, as reported in the journal Cancer
    Marie-France Demierre
    Department of Dermatology, Boston University School of Medicine, Boston, Massachusetts, USA
    Cancer 113:1728-43. 2008
  20. ncbi Melanoma: promising new discoveries and treatment modalities for difficult clinical scenarios
    Jonathan S Zager
    Cancer Control 15:192-4. 2008